Exogenous repletion of AAT, “augmentation therapy”, is recommended for select patients with emphysema, with weekly intravenous infusions of AAT purified from pooled human plasma (pAAT) [3, 4]. The gene discussed is SERPINA1; the disease is pulmonary emphysema.